The misfolding of intrinsically disordered proteins such as a-synuclein, tau and the Ab peptide has been associated with many highly debilitating neurodegenerative syndromes including Parkinson's and Alzheimer's diseases. Therapeutic targeting of the monomeric state of such intrinsically disordered proteins by small molecules has, however, been a major challenge because of their heterogeneous conformational properties. We show here that a combination of computational and experimental techniques has led to the identification of a drug-like phenyl-sulfonamide compound (ELN484228), that targets a-synuclein, a key protein in Parkinson's disease. We found that this compound has substantial biological activity in cellular models of a-synuclein-mediated dysfunction, including rescue of a-synuclein-induced disruption of vesicle trafficking and dopaminergic neuronal loss and neurite retraction most likely by reducing the amount of a-synuclein targeted to sites of vesicle mobilization such as the synapse in neurons or the site of bead engulfment in microglial cells. These results indicate that targeting a-synuclein by small molecules represents a promising approach to the development of therapeutic treatments of Parkinson's disease and related conditions.
Introduction
The aggregation and accumulation of a-synuclein (aSyn) constitutes the hallmark of a group of neurodegenerative disorders, often referred to as synucleinopathies, which include Parkinson's Disease (PD) [1] . In PD, aSyn accumulates in Lewy bodies as amyloid fibrils [2] . In addition, aSyn gene multiplications or missense mutations cause rare early onset forms of PD [3, 4, 5, 6, 7] and genetic association studies link aSyn to sporadic PD [8, 9] . Together, these findings strongly implicate aSyn as a key factor in the pathophysiology of PD. Monomeric aSyn is an example of an intrinsically disordered protein (IDP). IDPs can be represented as ensembles of interconverting conformations and are involved in many key biochemical processes [10, 11] , as well as in a growing number of misfolding diseases, notably the most common forms of neurodegenerative conditions [12, 13] .
A promising approach to remedying the aggregation and functional perturbations consequent to protein misfolding in disease is to use small molecule binding to stabilize the native states of proteins [14] . The development of such compounds has been successful in the case of globular proteins, such as transthyretin [15, 16] , a protein whose misfolding leads to systemic amyloidosis and related disorders, and glucocerebrosidase, a protein for which misfolding leads to Gaucher disease [17] . The structural heterogeneity and lack of persistent structural elements for aSyn and other IDPs, however, pose a major challenge in the discovery and design of small molecules for these proteins [18, 19] .
In silico screening methods based on high-throughput docking of large small molecule libraries to natively folded proteins have become an increasingly important strategy for initial lead discovery as a consequence of the wide availability of highresolution structures of protein targets and of the rapid advancement of computational and screening methods [19, 20] . Applying such methods to IDPs, such as aSyn is, however, not straightforward because of the lack of a well-defined target structure. Nevertheless, despite the absence of persistent structural elements, the conformational space populated by aSyn is not random and can be characterized at relatively high resolution by combining NMR spectroscopy with advanced structure computational methodologies [10, 21, 22] . These studies have revealed that aSyn populates a wide range of conformations in solution, including relatively compact but transient states resulting from the presence of residual local structure and long-range contacts within the fluctuating structural ensemble [23, 24] . Such residual local structure could provide an opportunity for small molecule discovery if appropriate binding pockets exist.
Such an expectation is based on the premise that small molecule binders to aSyn have the potential to bind to specific conformations present in the ensemble and modify its properties, which in turn could influence the way in which aSyn molecules interact among themselves and with other proteins. Thus, depending on which conformations of aSyn are involved, binding molecules could alter its aggregation propensity, or perturb the malfunction or the toxicity of aSyn that are associated with its over-expression [25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36] . Therefore, we set out to explore the potential of a drug discovery strategy designed to identify small molecules that can bind aSyn and then to test them in a diverse set of PD-relevant in vitro biochemical and cellular assays to look for potentially beneficial effects.
In addition to aggregation and toxicity resulting from aSyn misfolding, elevation of aSyn levels is also associated with the dysfunctional formation, localization, and maintenance of cellular vesicle pools [26, 31, 32, 34, 36] . A role for aSyn has been established in vesicle dynamics including impact on synaptic vesicle [27, 28, 29, 33, 34] , ER to Golgi trafficking [30] and exocytosis in both neuronal and non-neuronal cells [26, 32, 36] . Under physiological conditions, aSyn enhances neurotransmission through its effects on synaptic vesicle exocytosis or endocytosis [25] . In contrast, overexpression of aSyn affects select synaptic vesicle pools and reduces neurotransmission [31, 34] , and there is evidence for a link between the impact of aSyn on vesicle dynamics and aSyn-mediated toxicity [26] . The ability of aSyn to modulate membrane curvature, and the impact of aSyn on SNARE function have been postulated to be the underlying molecular mechanism by which aSyn plays such diverse roles in vesicle dynamics [37, 38, 39] . We have recently shown that phagocytosis, a process dependent on membrane expansion via focal vesicle extrusion to engulf particles [40, 41] , is impaired in cells and mice over-expressing aSyn and also in fibroblasts and blood cells from PD patients [42] . Thus, impairment of phagocytosis by elevated aSyn provides a cellular model of aSyn malfunction associated with its role on vesicle dynamics and in PD [42] .
In the present work we predicted small molecule binding sites present in a subset of aSyn conformations populated by the monomeric protein and screened for small molecules binding to these sites using an in silico structure-based computational docking screen. The application of this approach resulted in the discovery of several small-molecules predicted to bind to aSyn, among which, one compound (ELN484228), was characterized in particular detail in biochemical and cellular models. We have found that ELN484228 reverses aSyn-induced impairment of phagocytosis and protects dopaminergic neurons against the toxic effects of aSyn A53T over-expression. As a control we show that another compound, ELN484217, which is predicted to bind to a very different conformation of aSyn, does not impact aSyninduced impairment of phagocytosis. We thus provide evidence supporting a potential route for the development of therapeutic strategies for PD; in which aSyn is targeted by small molecules that can reverse aSyn-mediated malfunction.
Materials and Methods
A full description of methods can be found in the Supporting Information text file S1.
Ethics Statement
All animal work was conducted according to relevant national and international guidelines under protocols approved by Elan's Institutional Animal Care and Use Committee.
Molecular Modeling
Energy minimization of aSyn and small-molecule conformations and identification of hot spots are described in the Supporting Information text file S1 (Table S1 and Table S2 ). Docking calculations for a small-molecule library of 33,000 fragment-like compounds were carried out using FRED 2.0 (OpenEye Scientific Software, Inc., Santa Fe, www.eyesopen.com, 2008 and [43] , See a full description of docking method in the Supporting Information text file S1). After docking calculations, AM1/BCC charges were calculated for each ligand conformation and used in the subsequent minimization step. Optimization of the ligand in the binding site was performed by minimization of each docked conformation using SZYBKI 1.2.0 (OpenEye Scientific Software, Inc., www.eyesopen.com, 2008). During the SZYBKI minimization the MMFF94 molecular mechanics force field and the Poisson-Boltzmann solvation model was used. The protein structure was kept rigid while all the atoms of the ligand were allowed to be flexible.
Identification of hot spots and binding pockets was done using a computational fragment probe mapping methodology [19, 44, 45] (see also the Supporting Information text file S1). During this process, 15 different small molecules (fragment probes) (Fig. 1B) were docked onto the surfaces of the whole conformational set as described in the Supporting Information text file S1. The set of fragment probes used here contained diverse functional groups and shapes, which enabled them to bind to a variety of hot spots and binding sites. Hot spots were ranked using the potential ligand efficiency (L e ) score [19] . L e = g[E vdW/ (number of heavy atoms in a fragment probe)]/(number of fragment probes that bind the hotspot). Hot spots were located where the strongest interacting different fragment probes clustered. A potential binding pocket was identified when two or more high-ranking hot spots were in close proximity of each other. In the following we analyze two compounds (ELN484228 and ELN484217), which were identified through this procedure and are predicted to bind to two very different conformations of aSyn (Fig. S1 ).
aSyn Purification
Recombinant aSyn was produced in E. coli and purified under heat-denatured conditions using standard protocols [46, 47, 48] .
Aggregation Assays
Aggregation of aSyn was assayed in triplicates at 37uC under shaking (300 rpm) in solutions containing 50 mM protein in the absence and presence of tenfold higher concentration of compound ELN484228 in 25 mM Tris buffer pH 7.4, 100 mM NaCl with the addition of 0.01% NaN 3 . Aliquots were withdrawn on a daily basis and the thioflavin T (ThT) fluorescence signal was recorded after addition of 20 mM of ThT to each aliquot. Fluorescence emission spectra from 460 to 600 nm were then recorded at an excitation wavelength of 446 nm employing a Cary-Eclipse spectrofluorimeter (Varian, Palo Alto CA). Quenching of the ThT fluorescence by the addition of ELN484228 was assayed by incubating pre-formed fibrils with the compound and by comparison of the ThT fluorescence signal before and after the addition of ELN484228, but no significant change in signal was found. The aggregation of aSyn in the presence of ELN484228 was also characterized in the presence of low concentrations of SDS (200 mM) under the same experimental conditions as described above. The time-dependences of the ThT fluorescence signal were fitted to a nucleation-elongation model as previously described [49] . TEM images were obtained using a Philips CEM100 transmission electron microscope. The samples were applied on Formvar-carbon coated nickel grids and stained with 2% (w/v) uranyl acetate.
Transgenic Animals
A full description of the generation of transgenic animals is provided in the Supporting Information text file S1 and [42] . Briefly, Bacterial Artificial Chromosome (BAC) clone RP11-458H10, containing the human SNCA gene sequence (Life Technologies, Carlsbad, CA) was modified to generate both the Rep1 mutation [50] and E46K mutation [51] by BAC recombineering methods as described [52] . Circular BAC constructs containing the hSNCA transgene (,168 Kb) were used to perform pronuclear microinjection into B6SJL F2 mouse strains (The Jackson Laboratories, Bar Harbor, ME) in the concentration of 1-3 mg/ml followed by implantation into pseudo pregnant females (Xenogen Biosciences, Cranbury, NJ). Founder animals were bred with B6D2F1 mice and maintained as heterozygotes on this background with non-transgenic littermates as controls. Line BAC-Tg3(SNCA E46K ) animals were bred in sufficient numbers for a 3, 8-9, 12-14, 18-20 month old (MO) characterization cohorts and were 3-8 generations from founders. All mice were housed in a pathogen-free, climate controlled and given food and water ad libitum. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at Elan pharmaceuticals in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Primary Cell Cultures
Microglia were obtained from cerebral cortices of 1-3 day old neonate mice. A full description of microglia culture methods is provided in the Supporting Information text file S1. Hippocampal neurons were isolated from embryonic day 18 prenatal rat hippocampi and cultured in antibiotic-and serum-free NbActiv4 medium (both from BrainBits, Springfield IL) at 37uC in an atmosphere of 5% CO2, 9% O2 and on glass coverslips coated with poly-lysine. Half of the medium was replaced every 3 to 4 days. Cells were used for the experiments after 21-28 days in vitro.
Primary midbrain cultures were prepared from embryonic day 17 embryos of Sprague-Dawley rats using methods reviewed and approved by the Purdue Animal Care and Use Committee as described previously [30, 35, 53, 54] . After dissection, the cells were plated into a poly-L-lysine-treated 48-well plate at a density of 163,500 cells per well. Four days later, the cells were treated with cytosine arabinofuranoside (AraC) (20 mM) for 48 hours to inhibit the growth of glial cells. The cultures were used for measurements of dopaminergic neuron viability and neurite length at 7 days in vitro.
Primary cortical neurons were prepared from embryonic rats. Timed pregnant rats were obtained from Charles River Laboratories (Cambridge, MA). Primary cultures of rat cortical neurons were prepared from rat pup cortices on embryonic days 20-21. Cortices were dissected and treated with papain (10 units/ml, 15 minutes; (Worthington)) followed by addition of trypsin inhibitor (10 mg/ml, 15 minutes; Sigma). After trituration, dissociated neurons were plated on plastic 24 well plates coated with laminin (BD Biosciences) and poly-D-lysine (Millipore). Neurons were grown in Neurobasal-A with B27 medium (Invitrogen) and were used for experiments at 5-7 days in vitro (DIV). Neurons were transfected with plasmids using lipofectamine2000. Neurons were co-transfected with pCAGGS control and pGW1-RFP or pCAGGS aSyn and pGW1-RFP, in a 1:8 molar ratio. ELN484228 was added to the neurons at 1, 5 and 10 mM concentrations. The compound was added to the neurons directly after transfection and again at 72 and 120 hours post transfection. DMSO was used as a vehicle control.
Phagocytosis Assay
Isolated hSNCA E46K non-transgenic and aSyn transgenic mouse microglia were plated in 24-well plates at 1610 5 cells/ well for 1 day. Cells were then treated with various concentration of ELN484228 or ELN484217, another compound selected from the in silico hits (compound number 38 in table S4 in the Supporting Information text file S1), for 24 hours. 10 mm FluorSpheres particles, 5610 ' 6 10 m beads (Life Technologies) were washed with 1 ml of PBS 3 times to remove azide and added (1:10) for 90 minutes at 37uC. Unbound particles were washed away with PBS and cells were stained with Wright's Giemsa (Leukostat; Fisher, Freemont CA) for 30 seconds for each stain and phagocytosis was determined by light microscopy. A phagocytic index was calculated using the formula PI = (# particles ingested/ #cells counted)6100. 200 cells were visualized for each well and each condition was performed blinded in duplicate. A human neuroglioma H4 cell-derived cell line stably over-expressing aSyn from a tetracycline inducible promoter was generated using the tet inducible TRex system (Invitrogen division of Life Technologies) and selecting the clone with maximal induction and expression. For assessment of phagocytosis in H4 cells, cells were plated at 25,000 cells per 24 well plate and following an overnight incubation were treated with various concentration of ELN484228 or ELN484217 and tetracycline at 1 mg/ml to induce aSyn overexpression and cultured for an additional 24 hours. 4 mm FluorSpheres particles, (Life Technologies) were added at a ratio of 1:10 for 90 minutes, to assess phagocytotic capacity. Cells were fixed, stained and phagocytosis assessed as above.
Microscopy Analysis
For aSyn translocation analysis, H4 cells were plated and treated as in the phagocytosis assay, and the cells were fed 4 mm beads for 90 minutes. The cells were fixed with 4% PFA for 20 minutes, and then permeabilized with 0.5% saponin (SigmaAldrich, St. Louis, MO) and blocked with 1% BSA for 30 minutes on ice. 1 mg of primary antibody 5C12 was added overnight at 4uC, and cells were washed twice and incubated with 594-conjugated secondary antibody (1:100 dilution) for 30 minutes. Cell were washed twice in PBS and then stained for actin with 1:100 of Alexa488-phalloidin and the nuclear stain DAPI at 1:1000 for 30 minutes. Cells were visualized on an Olympus1X81 scope (Olympus, Center Valley NJ) with a 20X/0.45 objective or a 63X/0.70 objective. Digital images were taken using MetaMorph imaging software (Molecular Devices, Sunnyvale, CA).
For analysis of synaptic aSyn levels, primary hippocampal cultures were treated with 1 mM ELN484228 or the vehicle control (0.01% DMSO) in NbActiv4 media at 37uC for 24 hours. The cells were then fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and further incubated with primary antibodies for 24 hours at room temperature. These included a mouse anti-aSyn (5C12, Elan Pharmaceuticals [55] ) and a rabbit anti-synaptophysin (Millipore Corporation, Billerica, MA). The detection was performed after incubation with appropriate secondary antibodies conjugated to Alexa fluorophores (Life Technologies, InVitrogen). Any non-specific signal was determined by substituting primary antibodies with appropriate IgG controls. Digital images of fluorescently labeled cells were collected on a Leica SPE laser scanning confocal microscope (Leica microsystems, Wetzlar Germany) using a 63X objective. A total of 10 to 20 optical fields per group per experiment were randomly sampled by software. Fields containing fewer than 2 neurons were discarded. Images were analyzed with MetaMorph imaging system (Molecular Devices, Sunnyvale CA) and synaptic aSyn staining was determined by measuring the amount of fluorescent signal (average intensity) at the presynaptic sites, identified by the presence of the presynaptic marker synaptophysin.
Robotic Microscope Imaging System, Image Analysis and Related Statistics
For imaging of primary cortical neurons to assess aSyn impact on survival, images of neurons were taken at 24-hour intervals after transfection using the automated microscope system previously developed [56] . Image acquisition and analysis were carried out on ImagePro Plus 6.2. Measurements of aSyn neuron survival were obtained from files generated with automated imaging and visual inspection. Living transfected neurons were selected for analysis based on fluorescence intensity and morphology. Neurons were only selected if they have extended processes at the start of the experiment. The survival time of a neuron was measured as the last time point at which the neuron was seen alive.
For statistical analysis of primary cortical neurons to assess aSyn impact on survival, Kaplan-Meier curves were used to estimate survival using statview software package. Hazard ratios and their respective p-values were generated using the coxph function in the survival package for R statistical software [57] .
Dopaminergic Neuron Viability Assay & Neurite Length Analysis
Primary midbrain cultures were transduced with aSyn A53T adenovirus (MOI = 10), in the absence or presence of ELN484228, as described previously [35] . After 72 hours, the cells were incubated with fresh media with or without the compound for another 24 hours prior to immunocytochemical analysis, which was carried out as described previously [30, 35, 53, 54] . The cells were fixed, permeabilized, and blocked prior to an overnight treatment with two primary antibodies: a mouse monoclonal IgG specific for microtubule-associated protein 2 (MAP2) (1:500) and a rabbit polyclonal antibody specific for tyrosine hydroxylase (TH) (1:500). Next, the cells were treated with two secondary antibodies, goat anti-mouse IgG conjugated to AlexaFluor 594 and goat antirabbit IgG conjugated to AlexaFluor 488 (1:1000) for 1 hour. In order to determine the viability of dopaminergic neurons, MAP2-and TH-positive neurons were counted in 10 to 15 randomly chosen observation fields in a blinded manner using a Nikon TE2000-U inverted fluorescence microscope (Nikon Instruments, Melville NY) with a 20X objective. In the control conditions, and in conditions where the compound was neuroprotective, we typically counted 500 to 1,300 MAP2-positive neurons, a range that corresponds to 20 to 50 TH-positive neurons [53] . The data were expressed as the ratio of the TH-positive neurons to the MAP2-positive neurons. Each experiment was repeated at least three times using embryonic midbrain cultures from different pregnant rats. The neurite length analysis was carried out on the same samples used for the dopaminergic neuron viability assay.
Overlay images of MAP2-and TH-positive neurons were taken in a blinded manner using a Nikon A1 confocal microscope (Nikon Instruments, Melville NY), and neurite lengths were measured for 160 to 206 neurites per treatment (corresponding to $78 neurons pooled from three independent experiments) using the NISElements software. For both the neuron viability assay and the neurite length analysis, statistical analyses were carried out using the program GraphPad Prism, Version 6.0 (http://www. graphpad.com/prism/Prism.htm).
Results

Computational Identification of small Molecule Binders of aSyn
Our strategy to identify small molecule binders of aSyn is based on the description of the structural properties of IDPs in terms of conformational ensembles [19, 23, 24, 58, 59] . Here, we used an ensemble of structures determined by a combination of NMR and computational methods [24] as the basis for a three-step de novo computational screen to identify potential small molecule binders to aSyn. In the first step, 100 structures were randomly chosen from an ensemble of 40,000 NMR-derived aSyn conformations (Fig. 1A) . From this set, 22 diverse members were identified by a selection process with some bias towards the more compact conformations (open circles in Fig. 1A ; fully described in the Supporting Information text file S1 and Fig. S1 ), as these are more likely to offer binding pockets that are more suited for the binding of small molecules. In the second step, computational fragment probe mapping [44] was used to identify ''drugable hot spots'' located where the strongest interacting different fragment probes clustered (see Materials and methods and Supporting Information text file S1) [60] , on these 22 aSyn conformations (Fig. 1B) . This procedure led to the identification of eight binding pockets, each of which is located in a different member of the aSyn ensemble ( Fig. 1C and Table S2 ). Most of the sites identified are present at an interface involving relatively long-range tertiary contacts (Table  S3 ) between different regions of aSyn. In the third step, a library of drug-like small molecules, containing approximately 33,000 commercially available fragment-like compounds having a molecular weight under 325 Da, were docked individually to each of the eight different binding pockets. These calculations resulted in the identification of 89 compounds (referred to as in silico hits), representing a small fraction of the screened molecules as potential ligands for these binding pockets (between 9 to 18 binders for each pocket, table S2 and Fig. S2 ). These compounds were considered suitable candidates for an experimental test of their ability to impact aSyn (Table S4) . We chose one compound, ELN484228 (entry number 7 in Table S4 ), for further study in aSyn aggregation assays and in cellular models of aSyn malfunction, and as a control we chose another compound, ELN484217 (entry number 38 in Table S4 ), which is predicted to bind to a very different conformation of aSyn than that of ELN484228 as ELN484228 is predicted to bind to pocket I and ELN484217 to pocket IV (Table S4 and Fig. 1 ).
ELN484228 is Protective in Cellular Models of aSynmediated Vesicular Dysfunction
Although ELN484228 did not detectably modify aSyn aggregation in vitro when probed by ThT fluorescence (Fig. S3) , the screening procedure that we used has the potential to identify compounds affecting other aSyn mediated dysfunctions. aSyn overexpression can alter vesicular dynamics in cells including the impairment of phagocytosis [42] . We tested the effects of the compound in two cellular models in which aSyn overexpression
Targeting the a-Synuclein Structural Ensemble PLOS ONE | www.plosone.orgresults in defective phagocytosis. Both H4 neuroglioma cells overexpressing wildtype aSyn in a tetracycline regulatable manner (H4-syn) and microglia isolated from aSyn BAC transgenic animals overexpressing the E46K mutant form of human aSyn display impaired phagocytosis [42] . Previous experiments demonstrated that overexpression of control proteins including bsynuclein has no impact on phagocytosis [42] .
H4-syn cells were exposed to ELN484228 or another compound selected from the in silico hits, ELN484217, followed by tetracycline-induced overexpression of aSyn. Cells were fed 4 mm beads for 90 minutes and a phagocytic index was measured.
Multiple Western blot measurements demonstrate that levels of aSyn were unchanged by the addition of ELN484228 (data not shown). However, treatment with ELN484228, but not ELN4848217, restored phagocytosis in the aSyn overexpressing cells in a dose dependent manner, with a 30 mM solution restoring phagocytosis by 60%, and complete rescue of the aSyn mediated phagocytosis deficit occurring with 100 mM ELN484228 (Fig. 2A) . ELN484228 did not alter phagocytosis in cells not overexpressing aSyn. Restoration of phagocytosis following ELN484228 treatment was also assessed in aSyn overexpressing microglia isolated from aSyn BAC transgenic animals. Similar to what was observed in the H4-syn cells, ELN484228, but not ELN4848217, treatment restored phagocytosis to that observed in wild type microglia (Fig. 2B ) without altering overall aSyn levels (data not shown). Thus, in two different cellular paradigms, ELN484228 reverses the impairment of phagocytosis mediated by aSyn whereas ELN484217, which is predicted to bind to a different conformation of aSyn, has no impact on phagocytosis.
ELN484228 Alters Targeting of aSyn to the Phagocytic Cup and to Synapses
Previously we demonstrated that under resting conditions aSyn is evenly distributed in the cytoplasm of H4-syn cells, and that following the addition of beads, aSyn is recruited to the phagocytic cup [42] . The inhibition of phagocytosis by overexpressed aSyn is accompanied by altered vesicle mobilization, SNARE complex assembly and membrane extrusion [42] , which may be a result of the elevated aSyn levels at the phagocytic cup. The consequence of ELN484228 treatment on aSyn recruitment to the phagocytic cup was assessed in aSyn overexpressing cells after 24 hours of compound treatment. Fig. 2D shows that whereas aSyn was recruited to the site of bead binding and ingestion in untreated H4 cells overexpressing aSyn, treatment with ELN484228 prevents the redistribution of aSyn to the phagocytic cup, looking much more like the distribution observed in non-bead treated aSyn overexpressing H4 cells. Thus the accumulation of aSyn at the phagocytic cup under overexpressed conditions is prevented by ELN484228 and may contribute to the mechanism of protection in this model.
Reminiscent of the recruitment of aSyn to the phagocytic cup is the demonstrated recruitment of aSyn to the presynaptic terminal of mature synapses, where it regulates distinct pools of synaptic vesicles and when over-expressed impairs neurotransmitter release [28, 33, 34] . To extend our observations to neuronal systems, we first tested the impact of ELN484228 on the targeting of aSyn to synapses. Mature hippocampal neuronal cultures were treated with 1 mM of the compound and the synaptic levels of the protein measured by immunofluorescence. The assessment of the synaptic levels of aSyn was performed using an imaging-based procedure that measures the co-registration of the signal for the aSyn protein with that of the pan-presynaptic marker synaptophysin. Fig. 2E demonstrates that ELN484228 reduces aSyn targeting in rat primary neuronal cultures by 50%. A similar two-fold reduction in aSyn synaptic targeting was also seen in cortical cultures from human aSyn overexpressing transgenic mice and at doses of ELN484228 over a ten-fold dose range (data not shown). There were no changes in number of puncta or in mean intensity of synaptophysin/punctum (data not shown), indicating that the effect of the compound was directed to aSyn and did not involve synaptic remodeling. Western blot analyses demonstrate that overall levels of aSyn were unchanged by ELN484228 treatment (data not shown). This concentration of ELN484228 did not cause evident toxicity as measured by counting neuronal profiles and by monitoring synaptic density (synaptophysin). Signs of toxicity were observed at compound concentrations above 30 mM, where the loss of neurons was evident in light microscopy. As these experiments demonstrated impact at 1 mM compound in the absence of serum, we also tested restoration of phagocytosis in aSyn overexpressing H4 cells and showed that in the absence of serum ELN484228 also shows similar efficacy at 1 mM (data not shown). Thus we show that ELN484228 reduces the recruitment of aSyn to both the phagocytic cup and to mature synapses.
ELN484228 is Protective against aSyn-mediated Degeneration in Dopaminergic Neurons
To test the effects of ELN484228 on aSyn-induced neurotoxicity, we used a primary midbrain culture model of PD [54] . As a control, we first established that there is no detectable toxic effect on primary dopaminergic neurons exposed to 10 mM ELN484228 alone (Fig. S4) . Transduction of the primary cultures with an adenovirus encoding A53T aSyn, a PD-linked genetic mutant found to form toxic oligomeric species more readily than the wild type protein [5, 61] , results in a 30-40% reduction in the number of TH-immunoreactive neurons and a significant reduction in the length of neurites staining positive for both TH and MAP2 (Fig. 2C) . In contrast, transduction with a virus encoding the control protein LacZ has no effect on neuron viability or neurite length [53] (data not shown). In the presence of 10 mM ELN484228, however, the neurotoxicity induced by A53T aSyn was found to be significantly suppressed, and TH-positive neuron viability was restored almost to the levels observed in nontransduced or vector control transduced cultures (Fig. 2C) . In addition, treatment with 10 mM ELN484228 rescued the neurite retraction elicited by A53T aSyn in TH-and MAP2-positive neurons (Fig. 2C) . The magnitude of the neuronal rescue by ELN484228 is similar to that exhibited by Rab GTPases [30] and SIRT2 inhibitors [62] when examined in this assay showing that ELN484228 has substantial neuroprotective activity. We did not, however, observe protection in a distinct model of aSyn mediated neuronal death in which immature rat cortical primary neurons transiently transfected to overexpress aSyn are individually followed and scored for viability using a robotic microscope [63, 64] (Fig. S5) . This result could be a consequence of the lack of synapses in this alternative model at this early stage of primary culture as neuronal death is seen early within the 5 day imaging protocol [63, 64] . The mechanism of aSyn neurotoxicity is likely to be different in this model compared to that in the primary midbrain culture model, and is apparently not targeted by the compound.
Discussion
We have pursued a novel discovery strategy to identify drug-like small molecules capable of binding monomeric aSyn and then analyzed the effects of select small molecules resulting from this procedure in a diverse set of PD relevant biochemical and cellular assays. An advantage of this screening strategy is its potential to Figure 2 . ELN484228 provides protection in cellular models of aSyn-mediated dysfunction. A. ELN484228 alleviates aSyn-mediated impairment of vesicular dynamics. H4 neuroglioma cells over-expressing aSyn from a tetracycline inducible promoter were cultured for 24 hours in the absence or presence of 1 mg/ml tetracycline to induce aSyn and ELN484228 or control compound ELN484217 (compound number 38 in table S4 in Supporting Information text file S1). Open bars: without compound, black bars: with indicated amount of compound. Cells were assayed for phagocytic activity as a measure of aSyn-mediated impairment of vesicular function. 4 m beads were added for 90 minutes and a phagocytic index was calculated by microscopic visualization. Each sample was run in triplicate and experiments were run three independent times. The phagocytic indices for each individual experiment were averaged and statistical analyses run on the final averages from the three experiments. T-test analysis of the combined averages of the three experiments revealed a significant difference in phagocytosis between Tet-induced samples with and without ELN484228 (n = 3+/2 s.e.m *p#0.001 versus no compound Tet-induced sample). B. Microglia isolated from postnatal day 1 to 3 pups from hSNCA E46K transgenic (aSyn ) or non-transgenic littermates were incubated for 24 hours with 100 mM ELN484217 or ELN484228 followed by addition of 10 mm beads for 90 minutes. A phagocytic index was calculated by microscopic visualization (n = 3+/2 s.e.m *p#0.001). C. ELN484228 alleviates loss of dopaminergic neurons and neurite retraction induced by the A53T mutant of aSyn. Primary rat embryonic midbrain cultures were non-transduced ('control') or transduced with adenovirus encoding A53T aSyn, in the absence or presence of 10 mM ELN484228. The cells were then stained immunocytochemically for MAP2 and TH. Preferential dopaminergic cell death was assessed by evaluating the percentage of MAP2-positive cells that Targeting the a-Synuclein Structural Ensemble PLOS ONE | www.plosone.orgidentify compounds with a variety of effects related to aSyn malfunction or misfolding, and we have demonstrated that indeed this screening approach yields molecules with dramatic impact on aSyn malfunction in cells.
The initial challenge was to identify small molecules that bind to aSyn despite the lack of well-defined conformational states of the protein. To surmount this challenge, we first used in silico structurebased fragment mapping to identify a discrete set of eight potential binding pockets identified from 100 conformations of aSyn, which are part of a structural ensemble of the protein constructed using experimental NMR data and molecular dynamics simulations [24] . We then performed an in silico structure-based docking screen of 33,000 compounds to identify a group of in silico hit compounds with potential to bind to these eight binding pockets. Using this methodology, we identified diverse small molecules that likely bind aSyn and described one of them in detail (ELN484228). Further studies will be needed to establish whether ELN484228 or other hit compounds interact with their predicted binding pockets and conformations of aSyn. It is also possible that small molecules that bind monomeric forms could interact more strongly with more ordered species, such as oligomers and fibrils. In principle, NMR techniques could be used for testing these possibilities, but as they tend to measure the bulk collection of conformational states of aSyn, they are relatively insensitive in measuring the small perturbations on the ensemble from compounds binding to minor conformations due to large averaging of chemical shifts. More sophisticated NMR methodologies such as ligand-based approaches may thus be required for these studies.
These findings and recent theoretical [19] and experimental [65] observations on the Ab peptide associated with Alzheimer's disease suggest that IDPs in general may contain small-molecule binding sites in a subset of their conformational ensemble. Thus our fragment mapping and docking studies suggest that locallypersistent binding sites are present even within a diverse population of conformations of aSyn, similarly to the case of the Ab peptide [19] . Binding of small molecules to such pockets could result in altering the conformational ensemble of the protein and furthermore could have effects on the dynamics and thermodynamic stability of the various conformational states of aSyn. These results suggest that a practical strategy can be developed to target small molecules to transient pockets present within the ensemble of an IDP and, that once discovered, such molecules can have a dramatic impact on reversing aSyn cellular dysfunction. In order to test if this is a viable screening strategy we tested select compounds in assays of aSyn-induced malfunction and were able to demonstrate the identification of at least one compound, ELN484228, showing protection using this screening paradigm.
The role of aSyn in vesicle dynamics in neuronal and nonneuronal cells [26, 29, 32, 34, 36] is established, and a mechanistic link between the vesicular dysregulation and aSyn toxicity has been proposed [26] . We have reported that phagocytosis, a process involving vesicular mobilization and extrusion, is impaired by aSyn overexpression in cells and mice as well as in fibroblasts and blood cells from Parkinson's patients [42] . Thus, the repair of this deficit may be a potential therapeutic approach for PD. The activity of ELN484228 in the cellular models of phagocytosis demonstrates a novel and dramatic impact of a small molecule on cellular dysfunction mediated by elevated aSyn. The corresponding protection against aSyn-induced toxicity in primary rat dopaminergic neurons indicates that ELN484228 is also protective in a model more clearly reflective of PD neurodegeneration and in addition supports the hypothetical link between aSyn impact on vesicle dynamics and toxicity proposed by Lindquist and colleagues [26] .
The biological impact of ELN484228 indicates that our overall strategy of identifying aSyn binding compounds. We note, however, that we have not yet firmly proven that ELN484228 is engaging aSyn in the cells and that this process is mediating its impact. Although we have rationally selected ELN484228 to interact with aSyn, it may still have the biological activity that we report by engaging different targets. Further experiments will be needed to clarify this issue. Due to the difficulty inherent in demonstrating interaction of a ligand with a low abundance conformation of aSyn, in vitro as well as in the cell, this can be a challenging endeavor. The most sensitive methods for detection of interaction of compounds with the biologically critical conformations of aSyn may in fact be testing for impact on cellular function. aSyn dysfunction can arise from the ability to attain a particular minor conformation, and thus a bioassay can be much more sensitive than any bulk binding measurement. This would be particularly true if the compound is interacting with a conformation mediating the transition of aSyn to a biologically critical state such as binding to membranes. It is of note that in both the glial and neuronal cells that trafficking of aSyn to either the site of engulfment or to the synapse was associated with protective action of ELN484228, suggesting the possibility that ELN484228 may act on a conformation of aSyn or cellular process that is involved in this trafficking. To our knowledge this is the first report of a drugable small molecule that alters transport of aSyn and ameliorates the aSyn-mediated impairment of vesicular dynamics involved in phagocytosis.
We did not see protection in all models of aSyn-mediated neuronal toxicity. This result is likely to arise from the differences between the various models that we used. For example, our alternate model, in which ELN484228 did not show protection, utilizes immature rat cortical neurons, which have not yet formed synapses [63, 64] . aSyn is recruited to the presynaptic terminal of mature synapses where it regulates distinct pools of synaptic vesicles and when over-expressed impairs neurotransmitter release [28, 33, 34] . This is a critical issue as we show that ELN484228 also stained positive for TH. The lengths of neurites staining positive for both MAP2 and TH were measured using the NIS-Elements software. Data are plotted as the mean 6 s.e.m. n = 3 for neuron viability analysis; n = 160-206 for neurite length analysis. *p-value#0.05, ***p-value#0.001 versus aSyn A53T virus in the absence of compound; one-way ANOVA with Newman-Keuls post-test. D. ELN484228 reduces translocation of aSyn to the phagocytic cup. To assess aSyn translocation, H4 cells were treated with 100 mM ELN484228 and 1 mg/ml tetracycline for 24 hours; cells were then stimulated with 4 m beads for 90 minutes. Samples were fixed and stained with 5C12 antibody to detect aSyn (red). Cells were counterstained with 488-phalloidin (green) and Hoechts (blue). A dotted circle indicates the position of the bead. E. ELN484228 reduces translocation of aSyn to synapses. Rat hippocampal neurons (,21DIV) grown in serum-free conditions were treated for 24 hours with 1 mM ELN484228 or 0.01% DMSO vehicle. On the left side is a representative confocal microscopic image showing localization of aSyn (red) detected with 5C12 antibody, and localization of the presynaptic marker synaptophysin (green). Scale bar is 5 mm. Images were subjected to quantitative analysis and synaptic aSyn levels were determined as the amount of signal that colocalizes with the synaptic synaptophysin marker. Automated measurements were performed in Metamorph imaging analysis software to determine synaptic aSyn and synaptophysin levels by integrated intensity or pixel area, respectively. Values represent mean +/2 SEM, n = 1000 terminals (aSyn) or 18 optical fields (synaptophysin) per condition, and derived from 2-3 independent cultures. Quantitation demonstrates that ELN484228 reduces the synaptic levels of aSyn in rat hippocampal neurons. doi:10.1371/journal.pone.0087133.g002
reduces the recruitment of aSyn to the phagocytic cup and to mature synapses, and this alteration in recruitment may underlie the beneficial mechanism of action of ELN484228 in both the phagocytosis and neuronal toxicity models. It is tempting to speculate that the impairment of vesicular function by elevated aSyn at the phagocytic cup and at synapses is reversed by the reduction in recruitment of aSyn to those sites by ELN484228. The lack of protection in immature neuronal cultures and protection in mature cultures with synapses is consistent with this hypothesis and indicates that the mechanism of aSyn toxicity in these two models could be significantly different. Alternatively, additional factors in these models could account for the differing results. Dopaminergic midbrain cells are more vulnerable in PD than cortical neurons [1] and the differing biology of aSyn in this neuronal subtype could be relevant. In addition, mutant A53T aSyn is used in the dopaminergic culture experiments versus the use of wildtype aSyn in the cortical model and likewise could be key to the differing results as the mechanism of neuronal toxicity may be different between the wild type and A53T forms of aSyn. NMR studies suggest that the A53T mutation impacts the overall conformational ensemble of aSyn [66] . Nevertheless, it is not clear whether this mutation would impact the local and tertiary conformations of the pocket to which ELN484228 is predicted to bind, as computational analysis of the A53T mutant aSyn conformational ensemble has not been performed. Protection by ELN484228 against A53T aSyn induced neurotoxicity in dopaminergic neurons suggest that ELN484228 can interact with A53T aSyn.
ELN484228 reduced synaptic levels of aSyn in neuronal cultures from both wild type rats and from transgenic mice overexpressing aSyn by not more than two-fold. Thus the amount of aSyn does not go below 50% of endogenous levels even at high doses of ELN484228. This is probably why this compound does not induce toxicity in wild type cells at efficacious doses, as there is likely to be sufficient total aSyn at the synapse for proper modulation of neurotransmission. ELN484228 is a small molecule whose central element is a benzene-sulfonamide group, a functional moiety found in several dozen approved drugs such as the antibiotics sulfanilamide, sulfapyridine and sulfadiazine [67] and thus has drug-like potential. Thus, compound ELN484228 is likely to be a good starting point for development of a smallmolecule PD therapeutic designed to target aSyn.
In conclusion, we have reported that an in silico high-throughput structure-based docking screen resulted in the identification of several fragment-like small molecules predicted to bind to aSyn. These results support our findings that small molecule binding pockets can exist within members of the heterogeneous conformational ensemble of IDPs, including aSyn and the Ab peptide [19] despite their overall lack of persistent structures. One of our novel drug-like binders (ELN484228) was further characterized and found to be biologically active. The impact of ELN484228 on aSyn overexpressing cells results in significant amelioration of aSyn-induced cellular perturbations including impaired vesicular dynamics, neurotoxicity, and neurite retraction, all endpoints with therapeutic potential for PD. This is the first report of a drugable small molecule that alters transport of aSyn and ameliorates the aSyn-mediated impairment of vesicular dynamics involved in phagocytosis. This finding illustrates the potential value of this molecule as both a research tool and a lead compound directed against PD and related conditions [12, 68] . Further studies will be needed to verify that the engagement of aSyn in cells is mediating the protective effects of ELN484228. Overall, however, these results suggest that targeting small molecules to IDPs such as aSyn, has the potential to alter their properties in therapeutically relevant ways and provides a viable screening approach. Thus, such an integrated theoretical and experimental approach represents a promising drug discovery strategy for combating Parkinson's and other neurodegenerative diseases.
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